Continuing Education Questions
Continuing Education
1.The study comparing breast cancer risk in healthy women who carry germ-line BRCA1/2 mutations is notable for its:
- retrospective analysis.
- prospective, observational design.
- randomized, prospective design.
- mathematical modeling analysis.
2.In the CLL study of initial lenalidomide treatment, the median daily dose of lenalidomide prescribed for those considered long-term responders was:
- 2.5 mg.
- 5 mg.
- 10 mg.
- 25 mg.
3.In combined short-course RT, chemotherapy, and radical surgery trial for patients presenting with metastatic rectal cancer, the simultaneous resection of primary and metastatic disease was attempted at which point in the treatment sequence?
- Initially, before short course RT and chemotherapy
- After short-course RT, before systemic chemotherapy
- After systemic chemotherapy, before short-course RT
- After short-course RT and systemic chemotherapy
4.Which of the following best describes the Childhood Cancer Survivor study?
- It was a randomized, controlled, cohort trial.
- The primary study cohort were cancer patients under active treatment.
- Infertility was classified by two definitions — clinical and total infertility.
- Dosing of non-alkylating agents was indexed to measure effect on future fertility.
5.Current data from both the STIM and TWISTER studies would suggest that of patients treated with imatinib for 3 or more years who have had demonstrable deep molecular responses (i.e., undetectable BCR-ABL transcripts by RT/PCR), approximately what percent will remain with undetectable disease 2 years after discontinuation of imatinib?
- 90%
- 70%
- 40%
- 5%
Click here to take your CNE/CME test online.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.